We are proud to be the first Chinese Pharmaceutical company to fully market our own products within the UK, unlike other companies that trade and distribute other people’s products virtually. This means we know everything about our products – we are fully controlled from the production line, testing, packing and shipping to our UK Warehouse. Every stage is undertaken with the highest standards of quality control, a trait that has become synonymous with Sciecure and our products.
Our Chinese manufacturing plant has developed its quality management system so, it complies with international GMP standards, allowing our product manufacturing to be in compliance with China FDA, USFDA and EU GMP. Apart from our UK and China operation, we also have a business office and R&D laboratory in New Jersey, USA. This ensures our patients have the best quality product to help overcome their health challenges – globally.
With our dedicated UK sales & logistic team, this means we can consistently and constantly supply our products to fulfil the tightest of supply chain demands. We believe that supplying our product directly from our UK warehouse, not only saves our customers money but can be a real life-saving option for our patients and a perfect opportunity for GP’s or pharmacist’s to find the right products to treat their patients.
We know that if we want to go beyond our vision and make a real difference for the future of the pharmaceutical market we can’t just do it on our own. Therefore, we are constantly looking for opportunities to work with other companies that operate in the field. We believe that with the right connections and partnerships, we can truly make a difference for the future of pharmaceuticals and patient care.
We are committed to good corporate citizenship and the highest ethical standards. To fulfil these commitments, we establish and maintain systems and controls to safeguard against slavery and related human trafficking in our supply chain.
This Statement is made pursuant to Section 54 of the Modern Slavery Act 2015 and constitutes our slavery and human trafficking statement for the current financial year.